Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection

European Journal of Surgical Oncology

Volumn 33, Issue 7, 2007, Pages 832-837

  Kuijt, G P ^a,b   van de Poll Franse, L V ^c   Voogd, A C ^c,d   Nieuwenhuijzen, G A P ^e   Roumen, R M H ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Eindhoven Cancer Registry   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Lymph node dissection; Prognosis; Sentinel lymph node biopsy; Survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MITOSIS RATE; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

AGED; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TIME FACTORS;

EID: 34548050420     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.11.017     Document Type: Article

References (20)

1. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 1 (1989) 181-187
2. Purushotham A.D., Upponi S., Klevesath M.B., et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23 19 (2005) 4312-4321
3. Schulze T., Mucke J., Markwardt J., Schlag P.M., and Bembenek A. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 93 2 (2006) 109-119
4. Mansel R.E., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98 9 (2006) 599-609
5. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
6. Roumen R.M., Valkenburg J.G., and Geuskens L.M. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol 23 6 (1997) 495-502
7. Roumen R.M., Kuijt G.P., Liem I.H., and van Beek M.W. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 88 12 (2001) 1639-1643
8. Smidt M.L., Janssen C.M., Kuster D.M., Bruggink E.D., and Strobbe L.J. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12 1 (2005) 29-33
9. de Kanter A.Y., Menke-Pluymers M.M., Wouters M.W., Burgmans I., van Geel A.N., and Eggermont A.M. 5-Year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 32 3 (2006) 282-286
10. Naik A.M., Fey J., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 240 3 (2004) 462-468
11. Orr R.K. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 6 1 (1999) 109-116
12. Eindhoven Cancer Registry, Comprehensive Cancer Centre South. http://www.ikcnet.nl/ikz. 27-4-2006.
13. Mathiesen O., Carl J., Bonderup O., and Panduro J. Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients. Acta Oncol 29 6 (1990) 721-725
14. Kiricuta C.I., and Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 69 10 (1992) 2496-2501
15. Roumen R.M., Geuskens L.M., and Valkenburg J.G. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 25 4 (1999) 347-351
16. Bontenbal M., Nortier J.W., Beex L.V., et al. Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology. Ned Tijdschr Geneeskd 144 21 (2000) 984-989 [in Dutch]
17. van Diest P.J., van der W.E., and Baak J.P. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57 7 (2004) 675-681
18. Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 88 5 (2000) 971-977
19. Baak J.P., van Diest P.J., Voorhorst F.J., et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23 25 (2005) 5993-6001
20. Roumen R.M., Pijpers H.J., Thunnissen F.B., and Ruers T.J. Summary of the guideline 'Sentinel node biopsy in breast cancer.' Dutch Work Group 'Sentinel Node Biopsy for Breast Cancer'. Ned Tijdschr Geneeskd 144 39 (2000) 1864-1867 [in Dutch]